M
Manel Sabaté
Researcher at University of Barcelona
Publications - 607
Citations - 26779
Manel Sabaté is an academic researcher from University of Barcelona. The author has contributed to research in topics: Stent & Myocardial infarction. The author has an hindex of 63, co-authored 549 publications receiving 23775 citations. Previous affiliations of Manel Sabaté include Complutense University of Madrid & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Combined left atrial appendage occlusion with other transseptal procedures: should we use the same transseptal puncture?
Journal ArticleDOI
Emergent versus elective percutaneous stent implantation in the unprotected left main: long-term outcomes from a single center registry
Victoria Martin-Yuste,Luis Alvarez-Contreras,Salvatore Brugaletta,Clarissa Cola,Vicens Martí,Joan García-Picart,Manel Sabaté +6 more
TL;DR: Emergent PCI of the ULM exhibits worse in-hospital outcomes as compared to elective procedures, however, after discharge, long-term outcomes remain comparably good between groups.
Journal ArticleDOI
Platelet reactivity assessment with VerifyNow®: substitute or complement for light transmission aggregometry?
Ander Regueiro,Xavier Freixa,Diego Fernández-Rodríguez,Maribel Diaz-Ricart,Gines Escolar,Victoria Martin-Yuste,Salvatore Brugaletta,Manel Sabaté,Mónica Masotti +8 more
TL;DR: The objective of this study was to evaluate the correlation between light transmission aggregometry (LTA) and VerifyNow P2Y12 test with emphasis on patients with verified platelet reaction unit (PRU) after clopidogrel treatment, and to identify " good responders".
Journal ArticleDOI
Avances tecnol�gicos en el tratamiento de las enfermedades cardiovasculares: perspectiva de m�dicos y administradores
Pablo Lázaro,Manel Sabaté,Juan Sanchis,Enrique Puras Mallagray,Andrés Íñiguez Romo y,C. Macaya Miguel +5 more
Journal ArticleDOI
Treatment of device related thrombosis after left atrial appendage occlusion: Initial experience with low-dose apixaban.
Eduardo Flores-Umanzor,Pedro L. Cepas-Guillén,Ander Regueiro,Laura Sanchis,Felipe Unigarro,Salvatore Brugaletta,Marta Sitges,Manel Sabaté,Xavier Freixa +8 more
TL;DR: In this article, a case series is presented to summarize the experience of using apixaban at reduced doses for effectively treating device-related thrombosis (DRT) until device endothelialization occurs.